Perion Network Sees Upbeat Q2 Revenue; FDA's FTD Boosts Kazia
- July 06th, 2023
- 241 views
Perion Network Ltd. (Nasdaq: PERI) has released its preliminary results, revealing an anticipated second-quarter 2023 revenue of $176 million, marking a 20% year-over-year increase. This projection surpasses the consensus estimate of $169.88 million for the period.
In pre-market trading, $PERI was observed at $33.18, reflecting a notable rise of $2.30 (7.45%).
In other news, Kazia Therapeutics Limited (Nasdaq: KZIA) has obtained Fast Track Designation (FTD) from the FDA for its drug paxalisib, intended for the treatment of solid tumor brain metastases with PI3K pathway mutations in conjunction with radiation therapy.
FTD aims to accelerate the development of pharmaceutical products addressing unmet medical needs, granting Kazia enhanced access to the FDA, including accelerated approval and priority review possibilities, potentially facilitating faster product approval.
$KZIA was trading at $1.52 in pre-market, up $0.35 (29.91%) following the announcement
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
Earnings Preview: Walt Disney, Applied Materials, and Celcuity Take Center Stage
November 11th, 2024Key Metrics: CyberArk Software, Hudbay Minerals, and Sonos Earnings Due
November 11th, 2024Earnings: What to Expect from Occidental Petroleum, Rocket Lab, and CAE
November 10th, 2024Earnings Countdown: Home Depot, Sea Limited, and Natera in the Spotlight
November 10th, 2024Ahead of Earnings: DoorDash, MetLife, and Exelon in the Spotlight
October 27th, 2024
Member Login